RxDoctor Payments Data

Kirkland Nolan, MD

Pulmonary Disease · Round Rock, TXNPI 1982626347

Payments from drug & device makers

$673in general payments, 2019–2025

Across 31 payments — averaging $21.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$151
  • AstraZeneca$98
  • Boehringer Ingelheim$83
  • Regeneron Healthcare Solutions, Inc.$54
  • Viatris Specialty LLC$53
  • United Therapeutics Corporation$49
  • plus $185 from 8 others

What the payments were for

  • Food & beverage$673100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$673 in reported general payments places this provider in the 30th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$49,088
Medicare patients
484
Services billed
1,157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter300$228,831
OfevNintedanib Esylate13$108,867
Breo ElliptaFluticasone/Vilanterol70$37,332
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$17,239
Advair HfaFluticasone Propion/Salmeterol38$15,687
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$14,478
Fluticasone-SalmeterolFluticasone Propion/Salmeterol75$14,318
Spiriva HandihalerTiotropium Bromide19$11,332
Wixela InhubFluticasone Propion/Salmeterol73$11,138
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$9,828
Incruse ElliptaUmeclidinium Bromide24$8,702
SymbicortBudesonide/Formoterol Fumarate22$7,299
Albuterol Sulfate HfaAlbuterol Sulfate177$6,296
Arnuity ElliptaFluticasone Furoate16$5,392
DuleraMometasone/Formoterol15$5,178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$151$297,496434 claims
Boehringer IngelheimOfev, Stiolto Respimat$83$123,34525 claims
AstraZenecaBreztri Aerosphere, Symbicort$98$17,12738 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 904 pulmonary disease providers in Texas.

Other pulmonary disease in Round Rock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →